Choi, Hannah S JHannah S JChoiHirode, GrishmaGrishmaHirodeChen, Chien-HungChien-HungChenTUNG-HUNG SUSeto, Wai-KayWai-KaySetoVan Hees, StijnStijnVan HeesPapatheodoridi, MargaritaMargaritaPapatheodoridiLens, SabelaSabelaLensWong, Grace L HGrace L HWongBrakenhoff, Sylvia MSylvia MBrakenhoffChien, Rong-NanRong-NanChienFeld, Jordan JJordan JFeldSonneveld, Milan JMilan JSonneveldChan, Henry L YHenry L YChanForns, XavierXavierFornsPapatheodoridis, George VGeorge VPapatheodoridisVanwolleghem, ThomasThomasVanwolleghemYuen, Man-FungMan-FungYuenHsu, Yao-ChunYao-ChunHsuJIA-HORNG KAOCornberg, MarkusMarkusCornbergHansen, Bettina EBettina EHansenJeng, Wen-JueiWen-JueiJengJanssen, Harry L AHarry L AJanssen2023-02-062023-02-062023-0615423565https://scholars.lib.ntu.edu.tw/handle/123456789/627643Whether entecavir (ETV) and tenofovir disoproxil fumarate (TDF) differentially affect relapse and outcomes following treatment discontinuation across different patient subpopulations remains unclear. We aimed to compare rates of off-therapy hepatitis B surface antigen (HBsAg) loss, virological and clinical relapse, and retreatment between chronic hepatitis B (CHB) patients who discontinued TDF or ETV therapy.enChronic Hepatitis B; Entecavir; Nucleos(T)Ide Analogue Withdrawal; Off-Therapy Outcomes; Tenofovir[SDGs]SDG3journal article10.1016/j.cgh.2022.07.005358636832-s2.0-85140776334https://api.elsevier.com/content/abstract/scopus_id/85140776334